Comparison · NCT00796666-sae
Sitaxsentan and Placebo vs Sitaxsentan and Sildenafil: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Sitaxsentan and Placebo vs Sitaxsentan and Sildenafil: serious adverse events. Trial comparisons, record NCT00796666-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00796666-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.212 | 0.131 | 0.325 | wilson | |
| Risk in group 2 | 0.234 | 0.147 | 0.351 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0223 | -0.165 | 0.12 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.905 | 0.476 | 1.72 | log | |
| Odds ratio, group 1 over group 2 | 0.879 | 0.385 | 2.01 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Sitaxsentan and Placebo than on Sitaxsentan and Sildenafil | 44.9 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Sitaxsentan and Placebo | Sitaxsentan sodium (100 milligrams \[mg\]) orally once daily and placebo orally three times a day (TID) | 14 | 66 | EG000 |
| Group 2 | Sitaxsentan and Sildenafil | Sitaxsentan sodium (100 mg) orally once daily and sildenafil citrate (20 mg) TID | 15 | 64 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Source ClinicalTrials.gov
Trial
- Title
Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil
- NCT number
- NCT00796666
- Phases
- PHASE3
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Hypertension
- Interventions
- Sitaxsentan, Sitaxsentan and Sildenafil
- Lead sponsor
- Pfizer
- Results first posted
- 2012-02-29
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00796666?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00796666-sae